CKD-MBD post kidney transplantation

Area of Science:

• Nephrology
• Pediatric Endocrinology
• Bone Metabolism

Background:

• Chronic kidney disease-associated mineral and bone disorders (CKD-MBD) present significant complications in pediatric kidney transplant recipients.
• These complications include growth failure, bone deformities, fractures, osteonecrosis, and vascular calcification, leading to high morbidity.
• Preexisting renal osteodystrophy, cardiovascular changes, glucocorticoid use, and reduced graft function contribute to post-transplant CKD-MBD.

Purpose of the Study:

• To outline the complications of CKD-MBD in pediatric kidney transplant recipients.
• To detail the monitoring strategies for these patients.
• To recommend therapeutic approaches for managing CKD-MBD post-transplantation.

Main Methods:

• Review of existing literature on CKD-MBD complications in pediatric kidney transplant recipients.
• Analysis of factors contributing to post-transplant CKD-MBD.
• Synthesis of current monitoring and treatment guidelines.

Main Results:

• Elevated parathyroid hormone (PTH) and fibroblast growth factor 23 can cause hypophosphatemia and impair bone mineralization.
• Recommended monitoring includes growth, physical deformities, and serum levels of calcium, phosphate, magnesium, alkaline phosphatase, 25-hydroxyvitamin D, and PTH.
• Therapeutic strategies focus on physical activity, graft function preservation, steroid-sparing immunosuppression, vitamin D and mineral supplementation, and active vitamin D for hyperparathyroidism.

Conclusions:

• Effective management of CKD-MBD in pediatric kidney transplant recipients requires comprehensive monitoring and tailored therapies.
• Treatment aims to normalize mineral metabolism, suppress PTH levels, and prevent complications.
• Recombinant human growth hormone may be considered for patients with inadequate catch-up growth post-transplant.